ArticleBiochemistry and biophysics reports2025
Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Family with sequence similarity 72 (FAM72) plays a crucial role in the functions of neural stem cells, specifically in promoting the self-renewal capabilities of neural progenitor cells. The FAM72 family members FAM72A-D have been shown to play a role in tumorigenicity. However, their expression and prognostic significance in liver cancer remain unknown. In this study, we used bioinformatics analyses to assess the expression and prognostic relevance of FAM72A-D in liver cancer. The expression levels of FAM72A-D were markedly elevated in liver cancer tissues compared with normal tissues. FAM72A-D expression correlated with advanced clinical stage, high histological grade, and unfavorable prognosis in patients with liver cancer. Single-cell RNA sequencing results suggested that FAM72A-D are predominantly present in proliferative T cells. We examined genetic alterations in FAM72A-D and found that gene mutations were linked to low overall survival rates in patients with liver cancer. We further developed a robust FAM72 gene signature to predict the prognosis of patients with liver cancer, and the gene signature was associated with immune infiltration. Collectively, these findings indicate the involvement of the FAM72 family in liver tumorigenesis and suggest its potential utility as a biomarker for adverse prognostic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.